Immune health in older adults with advanced myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies the immune system of adults 65 and older with multiple myeloma that has come back or not responded to treatment. It looks at how their immune fitness may affect their ability to receive newer therapies like CAR-T cells or bispecific antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older
- You have multiple myeloma that has returned or did not respond to previous treatment
- Your doctor has said you can get CAR-T cell or bispecific antibody therapy
- You do not have another active cancer besides myeloma
- You do not have active AL amyloidosis
- Your myeloma has not spread to your brain or spinal cord
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
This trial tests a new treatment using your own immune cells, modified to find and attack a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has come back or not responded to at least three prior treatments.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.